NASDAQ:ANIX Anixa Biosciences (ANIX) Stock Price, News & Analysis $3.21 -0.15 (-4.46%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.14▼$3.4350-Day Range$2.21▼$3.4752-Week Range$2.14▼$5.13Volume78,607 shsAverage Volume118,177 shsMarket Capitalization$102.74 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Anixa Biosciences alerts: Email Address Anixa Biosciences MarketRank™ Stock AnalysisAnalyst RatingStrong Buy3.50 Rating ScoreUpside/Downside118.1% Upside$7.00 Price TargetShort InterestBearish2.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 3 Articles This WeekInsider TradingAcquiring Shares$185,948 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.43) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.17 out of 5 starsMedical Sector649th out of 910 stocksPharmaceutical Preparations Industry296th out of 426 stocks 3.8 Analyst's Opinion Consensus RatingAnixa Biosciences has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnixa Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Anixa Biosciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.31% of the float of Anixa Biosciences has been sold short.Short Interest Ratio / Days to CoverAnixa Biosciences has a short interest ratio ("days to cover") of 6.7.Change versus previous monthShort interest in Anixa Biosciences has recently increased by 0.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAnixa Biosciences does not currently pay a dividend.Dividend GrowthAnixa Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANIX. Previous Next 1.7 News and Social Media Coverage News SentimentAnixa Biosciences has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Anixa Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for ANIX on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Anixa Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anixa Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $185,948.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.60% of the stock of Anixa Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 29.13% of the stock of Anixa Biosciences is held by institutions.Read more about Anixa Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.43) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anixa Biosciences is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anixa Biosciences is -8.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnixa Biosciences has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Anixa Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Anixa Biosciences Stock (NASDAQ:ANIX)Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Read More ANIX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIX Stock News HeadlinesSeptember 6 at 11:32 AM | msn.comResearchers developing vaccine that could possibly prevent breast cancerSeptember 3, 2024 | prnewswire.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research SymposiumSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 26, 2024 | prnewswire.comAnixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 9, 2024 | uk.investing.comEF Hutton sets stock target on Anixa Biosciences sharesAugust 7, 2024 | msn.comEF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy RecommendationJuly 29, 2024 | msn.comAnixa Biosciences And 3 Other Stocks Under $5 Insiders Are BuyingJuly 29, 2024 | prnewswire.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual MeetingSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. July 28, 2024 | investing.comAnixa Biosciences director buys $15,450 worth of sharesJuly 26, 2024 | finance.yahoo.comWe're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash WiselyJuly 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy TrialsJuly 23, 2024 | msn.comCW39 New Breast Cancer Vaccine undergoing clinical TrialsJuly 23, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 23, 2024 | uk.finance.yahoo.comEXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T TherapyJuly 23, 2024 | prnewswire.comAnixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 17, 2024 | prnewswire.comAnixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine TechnologyJuly 15, 2024 | prnewswire.comAnixa Biosciences Announces $5 Million Share Repurchase ProgramSee More Headlines Receive ANIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anixa Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings6/04/2024Today9/07/2024Fiscal Year End10/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANIX CUSIPN/A CIK715446 Webwww.anixa.com Phone(408) 708-9808Fax631-549-5974Employees5Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+118.1%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,810,000.00 Net MarginsN/A Pretax Margin-5,174.29% Return on Equity-49.27% Return on Assets-45.55% Debt Debt-to-Equity RatioN/A Current Ratio14.40 Quick Ratio14.40 Sales & Book Value Annual Sales$210,000.00 Price / Sales489.23 Cash FlowN/A Price / Cash FlowN/A Book Value$0.75 per share Price / Book4.28Miscellaneous Outstanding Shares32,006,000Free Float24,773,000Market Cap$102.74 million OptionableOptionable Beta0.86 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Amit Kumar Ph.D. (Age 60)CEO, Chairman & Co-Chair of CBAB Comp: $1.29MMr. Michael J. Catelani CPA (Age 57)MBA, President, COO, CFO & Corporate Secretary Comp: $788.83kMr. John Roop (Age 74)Senior Vice President of Engineering Comp: $275kDr. Pamela D. Garzone Ph.D. (Age 69)Chief Development Officer & Chair Breast Cancer Clinical Advisory Board Key CompetitorsEnzo BiochemNYSE:ENZOpGenNASDAQ:OPGNPsychemedicsNASDAQ:PMDCryoportNASDAQ:CYRXTourmaline BioNASDAQ:TRMLView All CompetitorsInsiders & InstitutionsConcorde Asset Management LLCBought 13,969 shares on 8/12/2024Ownership: 0.044%Dimensional Fund Advisors LPSold 3,633 shares on 8/9/2024Ownership: 0.055%Lewis H Titterton JrBought 21,646 shares on 7/30/2024Total: $66,236.76 ($3.06/share)Nations Financial Group Inc. IA ADVBought 7,500 shares on 7/29/2024Ownership: 0.070%Arnold M BaskiesBought 5,000 shares on 7/26/2024Total: $15,450.00 ($3.09/share)View All Insider TransactionsView All Institutional Transactions ANIX Stock Analysis - Frequently Asked Questions How have ANIX shares performed this year? Anixa Biosciences' stock was trading at $3.88 on January 1st, 2024. Since then, ANIX stock has decreased by 17.3% and is now trading at $3.21. View the best growth stocks for 2024 here. How were Anixa Biosciences' earnings last quarter? Anixa Biosciences, Inc. (NASDAQ:ANIX) released its earnings results on Tuesday, June, 4th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. Who are Anixa Biosciences' major shareholders? Anixa Biosciences' top institutional shareholders include Bank of New York Mellon Corp (0.23%), Nations Financial Group Inc. IA ADV (0.07%), Dimensional Fund Advisors LP (0.05%) and Concorde Asset Management LLC (0.04%). Insiders that own company stock include Lewis H Titterton Jr, Amit Kumar, Arnold M Baskies and Michael Catelani. View institutional ownership trends. How do I buy shares of Anixa Biosciences? Shares of ANIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anixa Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anixa Biosciences investors own include Cronos Group (CRON), Innovative Industrial Properties (IIPR), Roku (ROKU), Ally Financial (ALLY), Albireo Pharma (ALBO), Air Lease (AL) and Akoustis Technologies (AKTS). This page (NASDAQ:ANIX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts